Comparative Pharmacology
Head-to-head clinical analysis: HYDROFLUMETHIAZIDE versus HYGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROFLUMETHIAZIDE versus HYGROTON.
HYDROFLUMETHIAZIDE vs HYGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
None Documented
None Documented
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."